Show simple item record

dc.contributor.authorBarriuso, Jorge
dc.contributor.authorLamarca, Angela
dc.contributor.authorMcNamara, Mairéad G
dc.contributor.authorManoharan, Prakash
dc.contributor.authorMoghadam, Sharzad
dc.contributor.authorRogan, Jane
dc.contributor.authorHayes, A
dc.contributor.authorMansoor, Was
dc.contributor.authorHubner, Richard A
dc.contributor.authorValle, Juan W
dc.date.accessioned2018-01-04T15:27:56Z
dc.date.available2018-01-04T15:27:56Z
dc.date.issued2017
dc.identifier.citationWhole-exome sequencing (WES) of samples from patients (pts) classified as exceptional responders (ER) vs poor responders (PO) to targeted therapies in pancreatic neuroendocrine tumours (pNETs). 2017, 105: 19-19 Neuroendocrinologyen
dc.identifier.urihttp://hdl.handle.net/10541/620755
dc.language.isoenen
dc.titleWhole-exome sequencing (WES) of samples from patients (pts) classified as exceptional responders (ER) vs poor responders (PO) to targeted therapies in pancreatic neuroendocrine tumours (pNETs).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie NHS Foundation Trust (ENETS Centre of Excellence). Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchesteren
dc.identifier.journalNeuroendocrinologyen


This item appears in the following Collection(s)

Show simple item record